Felipe A. Montellano
Research in cooperation with the Interdisciplinary Center for Clinical Research at the University of Würzburg / Research within the Clinician-Scientist Programme UNION –CVD (German Research Foundation)
Dr. med. Felipe A. Montellano
Phone: | +49 931 / 201 47318 |
Fax: | +49 931 / 201 647310 |
E-Mail: | montellano_f@ukw.de |
Short CV
since 2020 | Resident. Department of Neurology, Würzburg University Hospital |
since 2017 | Research Asssociate. Institute of Clinical Epidemiology and Biometry of the University of Würzburg (MD/PhD Fellow of the Interdisciplinary Center for Clinical Research at the Würzburg University Hospital) |
since 2016 | European Master in Stroke Medicine. Danube-University Krems. Austria (Scholar of the European Stroke Organisation) |
2015-2017 | Medical Doctoral Studies. Institute of Physiology and Pathophysiology. Neurovascular Research Group. Medical Faculty of the University of Heidelberg. (Prof. Dr. Hugo Marti) |
2014-2015 | Resident in Emergency Medicine, Clínica Dávila and Clínica INDISA. Santiago, Chile. |
2009 | Honours Scholarship, Faculty of Medicine of the Universidad de los Andes. Santiago, Chile |
2007-2013 | Medical School. Faculty of Medicine of the Universidad de los Andes. Santiago, Chile. |
Research interests
Acute stroke therapy, neurocritical care, emergency medicine.
Main Publications in recent years
2023[ to top ]
-
Systematic review on the effectiveness of mobile health applications on mental health of breast cancer survivors. Journal of Cancer Survivorship [Internet]. 2023;. Available from: https://doi.org/10.1007/s11764-023-01470-6.
- [ DOI ]
-
Persistent symptoms and risk factors predicting prolonged time to symptom-free after SARS‑CoV‑2 infection: an analysis of the baseline examination of the German COVIDOM/NAPKON-POP cohort. Infection. 2023;:1-16..
- [ DOI ]
-
Persisting chemosensory dysfunction in COVID-19 - a cross-sectional population-based survey. Rhinology. 2023;61(1):12-23..
- [ DOI ]
2022[ to top ]
-
Publisher Correction: Stroke genetics informs drug discovery and risk prediction across ancestries. Nature [Internet]. 2022;612(7938):E7-E7. Available from: https://doi.org/10.1038/s41586-022-05492-5.
- [ DOI ]
-
Cardiac dysfunction and high-sensitive C-reactive protein are associated with troponin T elevation in ischemic stroke: insights from the SICFAIL study. BMC Neurology [Internet]. 2022;22(1):511. Available from: https://doi.org/10.1186/s12883-022-03017-1.
- [ DOI ]
-
Stroke genetics informs drug discovery and risk prediction across ancestries. Nature. 2022;611(7934):115-23..
- [ DOI ]
-
Severity, predictors and clinical correlates of Post-COVID syndrome (PCS) in Germany: A prospective, multi-centre, population-based cohort study. EClinicalMedicine. 2022;51:101549..
- [ DOI ]
2021[ to top ]
-
Feasibility of platelet marker analysis in ischemic stroke patients and their association with one-year outcome. A pilot project within a subsample of the Stroke Induced Cardiac Failure in Mice and Men (SICFAIL) cohort study. Platelets [Internet]. 2021;33(5):772-80. Available from: https://doi.org/10.1080/09537104.2021.2002834.
- [ DOI ]
-
Role of Blood-Based Biomarkers in Ischemic Stroke Prognosis: A Systematic Review. Stroke. 2021;52(2):543-51..
- [ DOI ]
-
Long-term health sequelae and quality of life at least 6 months after infection with SARS-CoV-2: design and rationale of the COVIDOM-study as part of the NAPKON population-based cohort platform (POP). Infection. 2021;49(6):1277-8..
- [ DOI ]
2020[ to top ]
-
Prevalence and determinants of systolic and diastolic cardiac dysfunction and heart failure in acute ischemic stroke patients: The SICFAIL study. ESC Heart Failure [Internet]. 2020;8(2):1117-29. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/ehf2.13145.
- [ DOI ]